Evidence-Based Management of Adverse Events From Cancer Immunotherapy

Get expert insights on how the latest clinical data inform identification and management of challenging immune-related adverse events in patients with cancer who are receiving immune checkpoint inhibitors.
John Thompson Headshot
John A. Thompson, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: May 7, 2019 Expiration: May 6, 2020

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare the safety profile and tolerability of immune checkpoint inhibitors to chemotherapy
  • Understand the unique spectrum of potential immune-related adverse events of individual immune checkpoint inhibitors, including incidence, onset, and severity
  • Assess and manage specific types and grades of immune-related adverse events in patients receiving immune checkpoint inhibitors
  • Counsel patients to understand their prescribed therapy and be participants in the proactive identification and management of adverse events associated with cancer immunotherapy


Provided by the Annenberg Center for Health Sciences at Eisenhower

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Supported by an educational grant from
Bristol-Myers Squibb

Information on this Educational Activity

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


John A. Thompson, MD

Professor of Medicine
Division of Medical Oncology
University of Washington
Seattle, Washington

John A. Thompson, MD, has disclosed that he has received consulting fees from AstraZeneca, Calithera, and Synthorx.


Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no real or apparent conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with cancer being treated with immuno-oncology agents.


The goal of this activity is to improve the confidence, competence, and performance of oncology specialists and other clinicians caring for patients with cancer who are receiving treatment with immune checkpoint inhibitors and are at risk for experiencing an immune-related adverse event.

Physician Continuing Medical Education

Accreditation Statement

The Annenberg Center for health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 07, 2019, through May 06, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Results from CheckMate 9LA on first-line nivolumab + ipilimumab + 2 cycles of chemotherapy for advanced NSCLC from ASCO 2020, as reported by Clinical Care Options

Released: June 2, 2020

Updates on phase III CASPIAN study of durvalumab + tremelimumab + EP vs durvalumab + EP vs EP in SCLC from ASCO 2020, as reported by Clinical Care Options

Released: June 1, 2020

Experts review BTK inhibitor treatment recommendations in B-cell malignancies, like CLL, MCL, MZL, and WM, in these downloadable slides from CCO

Farrukh T. Awan, MD Ian W. Flinn, MD, PhD person default Prashant Kapoor, MD Released: May 29, 2020

From Clinical Care Options, download these slides with insights for nurses on new and emerging biomarkers critical to care of patients with gastrointestinal malignancies

Sara Toth, RN, MSN, FNP-C, AOCNP, AGN-BC Released: May 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?